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ThisstudyaimedtocharacterizetheHPVinfectionstatusinadolescentsandyounguniversitywomeninPortugal.Thedistribution
of HPV genotypes was evaluated by PCR DNA genotyping after self-sampling collection from 435 women of exfoliated cervical
cells using a commercial kit. We observed an overall frequency of HPV infection of 11.5%. Furthermore, HPV DNA prevalence
was 16.6% in those young women that self-declared as sexually active. The more frequently detected HPV types were 31, 16, 53,
and 61. Statistical analysis identiﬁed median age (OR = 3.56; P = 0.001), the number of lifetime sexual partners (OR = 4.50;
P<0.001), and years of sexual activity (OR = 2.36; P = 0.008) as risk factors for HPV acquisition. Hence, our study revealed that
oncogenic HPV infection is common in young asymptomatic women Portuguese women, with a history of 2–5 sexual partners
and over 2 year of sexual activity. Moreover, these results demonstrate that HPV detection performed in self-collected samples may
be important to appraise better preventive strategies and to monitorize the inﬂuence of vaccination programmes within diﬀerent
populations.
1.Introduction
Genital Human papillomavirus (HPV) is highly prevalent in
sexually active women. This infection has been established as
the etiological agents of genital warts and squamous intraep-
ithelial lesions of the cervix, and nevertheless, only certain
typesofHPVsareabletoinducecervicalcancerdevelopment
[1–3].
Cervical cancer is one of the leading causes of mor-
tality by cancer with approximately 495000 women newly
diagnosed each year [4]. In Portugal, cervical cancer is the
4th most frequent cancer with 950 new diagnosis and 378
deathsperyear,andthesecondmostfrequentamongwomen
between the age of 15 and 44 [5].
Adolescents and young-adult women are more vulnera-
ble to HPV infection. These observations are based on bio-
logical/physiological diﬀerences in the cervical epithelium.
While in adults the predominant cell type is squamous, in
adolescentsthepredominant celltypeis columnarand meta-
plastic [6]. However most HPV infections spontaneously
regress and only in a small percentage of cases the infection
persists, low-grade intraepithelial lesions progress to high-
grade lesions and, ultimately, develop into invasive cervical
carcinoma [7]. It is now accepted that persistent infection by2 Journal of Oncology
high-riskHPVsisanecessarybutnonsuﬃcientconditionfor
the development of cervical cancer [8].
HPV molecular detection has been implemented in sev-
eral countries and it was already proposed as the primary test
forscreeningbyreplacingthePapsmeartest[9–11].Whereas
HPV DNA tests have higher negative predictive value and
sensitivity than conventional Pap smear but poor positive
predictive value for identifying women with LSIL or cancer
[9–11], they may be extremely useful in the identiﬁcation of
women with none or low risk of developing intraepithelial
lesions [12].
Nevertheless,HPVgenotypingmaybeconsideredamore
important methodology than detection only, since it helps to
identifythepersistentinfectionswhicharepredictiveofHPV
infection outcome (development of intraepithelial lesions or
cervical cancer). Several in-house methodologies for HPV
genotyping have been developed in hospitals and research
centres, and they are ﬁnancially advantageous to detect and
characterize HPV in clinical specimens [13, 14].
Despite the incidence and mortality rates of cervical can-
cerinPortugal,untilnownonationalscreeningprogramwas
implemented and there is no suﬃcient epidemiological data
for HPV infection, particularly in young women. Screening
programs in young women are essential to understand
not only the epidemiology of HPV but also behaviours
and community practices and consequently prevent the
propagation of infection. Adolescents should be educated
regarding HPV and associated risk factors of infection.
Hence, they should also be encouraged to obtain suitable
gynecological cares after initiating sexual activity [15, 16].
Several studies have reported lately that self-obtained
samples from the anogenital tract were accurate and suitable
for HPV-DNA testing and have shown a similar correlation
to clinically obtained samples [17, 18]. Self-sampling does
not require a vaginal speculum examination by clinicians,
therefore it reduces the discomfort that turns screening
unattractive even among women who have access to health
cares. Besides, studies showed that HPV DNA test from self-
collected samples has sensitivity equivalent or even superior
to the cytological test [12, 17, 19].
The present study is the ﬁrst to characterize the presence
of HPV in adolescents and university women from northern
region of Portugal using the self-sampling method.
2.Subjects,Materials,andMethods
2.1. Study Population. A population-based study was devel-
opedtoobtainaproﬁleofHPVinfectionstatusintheNorth-
ern region of Portugal. Between March and May 2010,
female students aged from 14 to 30 years old, from eight
high schools and two university institutions from northern
region of Portugal, were invited to participate in the study.
Ethics approval was obtained from the Ethics Committee
of University Fernando Pessoa and all individuals included
in the study gave their informed consent according to the
Declaration of Helsinki, which in the case of women younger
than 18 years was signed by parents/guardians, in accordance
with the Portuguese legislation.
This study was undertaken in 435 women (median age
17.0 ± 2.46 years old), who have answered an anony-
mous questionnaire for epidemiological characterization.
Thestudypopulationwascharacterizedaccordingtoage,age
of menarche (median age 12.0 ± 1.34), education level, HPV
vaccination, sexual activity (n = 277,63.7%), age at ﬁrst
sexualactivity(16.0±1.67),numberofyearsafterﬁrstsexual
intercourse (2.0 ± 2.06), and lifetime number of partners
(Table 1).
2.2. Specimen Collection. All participants were volunteers
and informed of the study through workshops developed
speciﬁcally to explain the study and self-sampling proce-
dure. Brieﬂy, exfoliated cervical cells were collected by self-
samplingusingthecommercialkitUniversalTransportMedia
(UTM) from Digene (Digene, Brasil), which contains a
conical brush and a tube with transport media to stabilize
the sample. The self-collection process consists to inserting a
sterile brush into the vagina until their ﬁngers reached their
labia, and then rotating the brush ﬁve times in the same
directionandremovewhichfromthevaginaandplacewhich
in UTM as suggested by the commercial kit instructions.
2.3. HPV Analysis and Genotyping. Sample processing in-
cluded the concentration of cells by centrifugation, followed
by DNA extraction using QiAmp DNA Blood mini Kit
(QIAGEN, Hilden, Germany), according to manufacturer’s
instructions. DNA quality was assessed by measuring the
absorbance at 260nm using a UV/Visible spectrophotometer
anditspurityassessedbytheratioofthevaluesofabsorbance
at 260/280nm.
To assess the validation of extraction method, the pres-
ence of genomic DNA was tested with a PCR protocol for
ampliﬁcation of beta-globin gene with the PCO3 primer 5 -
ACA CAA CTG TGT TCA TAG C-3  and BGII primer 5 -
GTC TCC TTA AAC CTG TCT TG-3 .
ThePCRreactionwasperformedina50μLsolutionwith
1x Taq buﬀer, 4.0mM MgCl2,0 . 2 m MD N T P ’ S ,0 . 3 0 μM
each primer, 1U de Taq DNA Polimerase, and 0.2ug of
genomic DNA. The ampliﬁcation conditions were as follows:
denaturation of DNA template at 95◦C for 3min, followed
by 35 cycles of 94◦C for 1min, 55◦C for 1min, 72◦Cf o r
1min, and a ﬁnal extension step at 72◦C for 10min. The
ampliﬁed fragment of 175 base pairs (bp) was analyzed
by electrophoresis in 1.5% (w/v) agarose gels stained with
ethidium bromide and visualized under UV light.
HPVDNAwasdetectedthroughPCRusingtwodiﬀerent
pairsofconsensusprimers:GP5+/6+,whichamplifyaregion
of 150bp [20]; and MY09/11 degenerated primers, which
amplify a region of 449–458bp depending on HPV type
(as previously reported [1]). Both sets of primers amplify
a highly conserved region of the HPV L1 gene and are
potentially capable of detecting a large number of mucosal
HPV types in a single PCR reaction [21].
PCR ampliﬁcation reaction with GP5+/6+ primers was
carried in a 50μL of reaction mixture with 1x PCR Buﬀer,
3.0mM MgCl2, 0.2mM DNTP’S, 0.30μMo fe a c hp r i m e r ,
1UofTaq DNA polymerase, and 0.2ug of genomic DNA.Journal of Oncology 3
Table 1: Characteristics of the study participants.
Age and sexual intercourse n (%)
Age (median ± sda) 17.0 ± 2.46 (range 14 to 30)
A g eo fm e n a r c h e( m e d i a n± sda) 12.0 ± 1.34 (range 8 to 16)
Age of ﬁrst sexual intercourse (median ± sda) 16.0 ± 1.67 (range 13 to 22)
Number of years after ﬁrst sexual intercourse (median ± sda)2 . 0 ± 2.06 (range 0 to 12)
Education level (n = 434)
Elementary (≤9th grade) 27 (6.2)
High school (10th–12th grade) 296 (68.2)
University 111 (25.6)
HPV vaccination (n = 435)
Yes 161 (37.0)
No 231 (53.1)
NRb 43 (9.9)
Sexual activity (n = 435)
Yes 277 (63.7)
No 38 (8.7)
NRb 120 (27.6)
N o .o fS e x u a lp a r t n e r s( n = 277)
1 174 (62.8)
2–5 94 (33.9)
NRb 9 (3.3)
aStandard deviation; bNonresponders.
Thermal cycling was performed as follows: initial denatura-
tionofDNAtemplateat95◦Cfor4min,followedby40cycles
of 94◦C for 30s, 44◦C for 60sec, 72◦C for 90s, and a ﬁnal
extension step at 72◦C for 10min. The ampliﬁed fragment
was analyzed by electrophoresis in 1.5% (w/v) agarose gels
stained with ethidium bromide and visualized under UV
light.
PCR ampliﬁcation reaction with MY09/11 was per-
formed in a 50μL of reaction mixture with 1x PCR Buﬀer,
4.0mM MgCl2, 0.2mM DNTP’S, 0.40μMo fe a c hp r i m e r ,1
unit of Taq DNA polymerase, and 0.2ug of genomic DNA.
The ampliﬁcation conditions include an initial denaturation
at 95◦C during 3min, followed by 40 cycles of 94◦Cf o r
45s, 55◦C for 45s, 72◦C for 1min, and a ﬁnal extension
step at 72◦C for 5min. The ampliﬁed fragment was analyzed
by electrophoresis in 1.5% (w/v) agarose gels stained with
ethidium bromide and visualized under UV light.
HPV-positive cases by ampliﬁcation with primers
MY09/11 were typed by RFLP analysis as described by Nobre
et al. in 2008 [14]. Each restriction endonuclease reaction
wasperformedin a 20μL ﬁnal volume reaction, using 5μLo f
MY09/11PCRproduct,2μLof10xrecommendedrestriction
buﬀer, and 10 units of each restriction endonucleases: PstI
(New England BioLabs, R0140S), HaeIII (Fermentas Inc.,
#ER0151, Canada), DdeI (New England BioLabs, R0175L),
and RsaI (New England BioLabs, R0167S). Digestion was
performed at 37◦C for 5 hours. The restricted fragments
were separated by electrophoresis on 3% agarose gels with
ethidium bromide staining and visualized under ultraviolet
light. The identiﬁcation of HPV types was executed using the
algorithm proposed by Nobre et al. in 2008 [14].
The deﬁnition of HPV positivity was based on the
result of MY09/11 and/or GP5+/6+ PCR ampliﬁcation.
Nonconcordant results by both primer sets were sent to
sequentiate for conﬁrmation of result. HPV genotyping was
performed in MY09/11 positive cases and HPV genotypes
were divided into four groups based on their oncogenic
activity: high-risk types (HPV 16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, and 59), probable high-risk types (26, 53, 66, 68,
73, 82), low-risk types (6, 11, 13, 40, 42, 43, 44, 54 and 55,
61, 70, 72, 81, and 89), and types of undetermined risk (30,
32, 34 and 64, 62, 67, 69, 71, 74, 83, 84, 85, 86, 87, 90, 91, 97,
102, 106) [22, 23].
2.4. Quality Criteria. To ensure the quality of the study,
the following quality criteria were deﬁned: (1) blind study;
(2) inclusion of negative and positive controls in all PCR
reactions: as negative control we have used double distilled
water (dd H2O) replacing template DNA in the reaction mix;
and as positive control we used an HPV positive sample used
in the Virology Service for diagnosis of HPV infection using
the commercial kit hc2 High-Risk HPV DNA test (QIAGEN,
Hilden, Germany); (3) repetition of 100% of samples for
validation of results; and (4) analysis of both PCR and RFLP
results individually by three of the authors. Nonconcordant
results were sent to sequentiate for conﬁrmation of result.
2.5. Statistical Analysis . Statistical Analysis was performed
using the computer software Statistical Package for Social
Sciences version 16.0 for Mac. Chi-square (χ2)t e s tw a s
used to compare frequencies among groups. The OR (Odds
Ratio) and its 95% Conﬁdence interval were calculated as4 Journal of Oncology
Table 2: Distribution of HPV in sexually active women.
HPV positive
n (%)
HPV HRa
n (%)
HPVpHRb
n (%)
HPVLRc
n (%)
HPV URd
n (%)
INCe
n (%)
Total (n = 277) 46 (16.6) 19 (41.3) 7(15.2) 8 (17.4) 7(15.2) 5 (10.9)
Age (n = 277)
≤17 (n = 107) 8 (7.5) 6/8(75.0) — — 1/8 (12.5) 1/8(12.5)
18–20 (n = 104) 19 (18.3) 6/19(31.6) 3/19 (15.8) 3/19(15.8) 4/19 (21.0) 3/19(15.8)
>20 (n = 66) 19 (28.8) 7/19(36.9) 4/19 (21.1) 5/19(26.3) 2/19 (10.5) 1/19 (5.3)
≤17 (n = 107) 8 (7.5) 6/8(75.0) — — 1/8 (12.5) 1/8(12.5)
>17 (n = 161) 38 (22.4) 13/38(34.2) 7/38 (18.4) 8/38(21.1) 6/38 (15.8) 4/38(10.5)
Age at ﬁrst menarche (n = 275)
≤12 (n = 151) 26 (17.2) 9/26(34.6) 5/26 (19.2) 4/26(15.4) 5/26 (19.2) 3/26(11.5)
>12 (n = 124) 20 (16.1) 10/20(50.0) 2/20 (10.0) 4/20(20.0) 2/20 (10.0) 2/20(10.0)
Age at ﬁrst sexual intercourse
(n = 271)
≤16 (n = 143) 22 (15.4) 10/22(45.4) 4/22 (18.2) 2/22(9.1) 4/22 (18.2) 2/22 (9.1)
>16 (n = 128) 24 (18.8) 9/24(37.5) 3/24 (12.5) 6/24(25.0) 3/24 (12.5) 3/24(12.5)
N o .o fS e x u a lp a r t n e r s( n = 268)
1( n = 174) 15 (8.6) 8/15(53.3) 1/15 (6.7) 2/15(13.3) 3/15 (20.0) 1/15 (6.7)
2–5 (n = 94) 28 (29.8) 10/28(35.7) 4/28 (14.3) 6/28(21.4) 4/28 (14.3) 4/28(14.3)
No. of years after ﬁrst sexual
intercourse (n = 271)
≤2( n = 181) 23 (12.7) 11/23(47.9) 2/23 (8.7) 3/23(13.0) 3/23 (13.0) 4/23(17.4)
>2( n = 90) 23 (25.6) 8/23(34.8) 5/23 (21.7) 5/23(21.7) 4/23 (17.4) 1/23 (4.3)
Education level (n = 276)
Nonuniversity (n = 180) 23 (12.8) 11/23(47.9) 4/23 (17.4) 1/23(4.3) 2/23 (8.7) 5/23(21.7)
University (n = 96) 23 (24.0) 8/23(34.8) 3/23 (13.0) 7/23(30.5) 5/23 (21.7) —
HPV vaccination (n = 251)
No (n = 154) 34 (22.1) 13/34(38.2) 7/34 (20.6) 7/34(20.6) 4/34 (11.8) 3/34 (8.8)
Yes (n = 97) 9 (9.3) 5/9(55.6) — — 3/9 (33.3) 1/9(11.1)
aHigh-risk HPV; bProbable high-risk HPV; cLow-risk HPV; dUndeterminated- risk HPV; eInconclusive. The frequencies represented in the bold values of the
table refer only to HPV-positives cases.
ameasureoftheassociationbetweenthecategoricalvariables
(mean age, mean age of menarche, mean age of ﬁrst sexual
intercourse, educational level, and lifetime number of sexual
partners) and HPV infection status.
3. Results
3.1. HPV Distribution. The presence of HPV was tested
in 435 samples obtained by self-collection from young
women and 50 positive cases were identiﬁed. Positive cases
included one case from women who referred no initiation of
sexual activity and 3 from which such information was not
provided. For data analysis, we have considered only women
who referred to have initiated sexual activity (n = 277),
where HPV infection had a prevalence of 16.6% (46/277)
(Table 2).
HPV infection was analyzed according to age, age of
ﬁrst menarche, age of ﬁrst sexual intercourse, number of
yearsafterﬁrstsexualintercourse,numberofsexualpartners,
educational level, and HPV vaccination status (Table 2).
When comparing the frequency of HPV regarding, the
number of lifetime sexual partners, we observed increased
frequency of HPV among those who had 2–5 partners
(29.8%) and women who initiated sexual activity over two
years have a higher frequency of HPV infection (24.0%).
WeobservedthatHPVwasmorefrequentamonguniver-
sity students (24.0%) compared with nonuniversity students
(12.8%). However, within positive cases, the prevalence of
high-risk HPV was higher for nonuniversity students in
comparison to university students (47.9% versus 34.8%)
(Table 2). Overall, 19 HPV diﬀerent types were detected: 6
high risk (HPV16, 18, 31, 45, 56, and 58); 2 probable high
risk (HPV53 and 66), 4 low risk (HPV6, 54, 61, and 89); and
7 types of unknown-risk (HPV30, 32, 71, 84, 86, 87, and 97)
(Table 3). Notably, the most frequent types of HPV found
in the study were the high-risk types, with HPV31 being
the most frequent (15.2%) followed by the HPV16 (13.0%),
HPV53, and HPV61 (8.7%).
3.2. Risk Estimation for Epidemiologic Characteristics. Sta-
tistical signiﬁcant diﬀerences were found when comparing
HPV distribution regarding education level, HPV vaccina-
tion, mean age, lifetime number of sexual partners, and
number of years after ﬁrst sexual intercourse (Table 4). WeJournal of Oncology 5
Table 3: Distribution of diﬀerent HPV types.
HPV positive cases (n = 46) n (%)
HR HPVa (n = 19)
16 6 (13.0)
18 2 (4.3)
31 7 (15.2)
45 1 (2.2)
56 1 (2.2)
58 2 (4.3)
pHR HPV (n = 7)
53 4 (8.7)
66 3 (6.5)
LR HPVc (n = 8)
61 ( 2 . 2 )
54 2 (4.3)
61 4 (8.7)
89 1 (2.2)
UR HPVd (n = 7)
30 1 (2.2)
32 1 (2.2)
71 1 (2.2)
84 1 (2.2)
86 1 (2.2)
87 1 (2.2)
97 1 (2.2)
Nonidentiﬁed (n = 5)
aHigh-risk HPV; bProbable High-risk HPV; cLow-risk HPV; dUndetermi-
nated- risk HPV.
found a strong correlation between the presence of HPV in-
fection and women aged over 17 years old (OR = 3.56; 95%
CI 1.59–7.97; P = 0.001), women with 2–5 sexual partners
(OR = 4.50, 95% IC 2.26–8.96, P<0.001), and women who
had initiated their sexual activity over 2 years (OR = 2.36,
95% IC 1.24–4.49, P = 0.008).
4. Discussion
HPVinfectionisoneofthemostcommonsexuallytransmit-
ted infections and a major public health concern, especially
during adolescence [24, 25]. Most HPV infections are
asymptomatic and are eﬃciently controlled by the immune
system, therefore, the outcome of HPV infection is variable,
the infection is usually transient, and complete resolution
is generally common within 12 to 24 months [26, 27].
However, persistent infection with one or more carcinogenic
types of HPV may lead to the emergence of intraepithelial
lesions, which may progress to high-grade dysplasia or in
severe cases to invasive carcinoma [7].
Due to the worldwide distribution of HPV infection and
to the high-incidence in undeveloped countries, many com-
panies have attempted to developed low-cost tests with high
eﬃciency to detect HPV. Self-sampling has been suggested
as a useful tool for testing women for HPV infection mainly
in low-resource populations or for people who have diﬃcult
Table 4: Odds Ratio (OR) analysis for HPV.
P OR
a 95%
CIb
Education level
University versus nonuniversity 0.018 2.15 1.13–
4.08
HPV vaccination
Vaccinated versus nonvaccinated 0.009 0.36 0.16–
0.79
Median age
≤17 versus >17 0.001 3.56 1.59–
7.97
Median age ﬁrst menarche
≤12 versus >12 0.810 0.92 0.49–
1.75
Median age ﬁrst sexual intercourse
≤16 versus >16 0.461 1.27 0.67–
2.40
N o .o fs e x u a lp a r t n e r s
1v e r s u s2 – 5 <0.001 4.50 2.26–
8.96
No. of years after ﬁrst sexual intercourse
(n = 271)
≤2v e r s u s>2 0.008 2.36 1.24–
4.49
aOdds Ratio; bConﬁdence interval.
access to health care [12]. Self-sampling has been referred
to as having more than a few advantages compared with
physician-collected samples for detection of HPV genital
infection [17]. Self-sampling is a less costly and noninvasive
method; it reduces the discomfort that some women asso-
ciate to medical examination and the uneasiness that make
screening programs less pleasant, even in women who have
access to health care services [17, 28]. Several studies have
shown that self-sampling has sensitivity for detecting lesions
with low and high grade and even invasive cancer, which is
equivalent or even superior to Pap smear [17, 18]. A recent
meta-analysis revealed that self-sampling had a sensitivity
≥70% and a speciﬁcity of 88% compared to physician-
sampling to detect the presence of HPV infection [29].
Although the number of samples was limited and further
large-scale epidemiological studies are needed to assess the
signiﬁcance of less common genotypes, this study provides
the ﬁrst view on the spectrum of the most common mucosal
HPV types in young Portuguese women.
Epidemiologic studiesrefertoaprevalenceofHPVinfec-
tion from 2% to 44% in general population, with the highest
p r e v a l e n c ei nw o m e na g e d2 0t o2 4y e a r so l d[ 30, 31].
Our results showed an overall frequency of 11.5% (50/435)
positive cases for HPV, and considering sexual activity as
an important discriminating factor for HPV acquisition,
the frequency among young sexually active women was of
16.6% (46/277). This frequency is similar to those found
in other studies, which refer that HPV infection among6 Journal of Oncology
asymptomaticwomenmayvaryfrom12to31.4%depending
on the population [32–36].
According to several studies, the behavioral risk factors
associated with the HPV infection in adolescents and young
adult women include early age of ﬁrst sexual intercourse
[24, 37–39]. However, in our population sample, the age
of ﬁrst sexual intercourse did not seem to be a cofactor for
HPV infection. Nevertheless, our results suggest that age
is an important factor for HPV infection and it was more
frequent in young women aged more than 17 years old
than in younger women. Once more, these results are
in agreement with several other studies referring to HPV
infection as consistently more common in sexually active
younger women [40].
T h en u m b e ro fl i f e t i m es e x u a lp a r t n e r si sc o n s i d e r e dt o
be one of the major risk factors for HPV infection [39],
and in our study, we observed that women with more than
one sexual partner (2 to 5 partners) are associated with an
increased probability of HPV infection. Furthermore, we
observed increased probability of infection in women who
had initiated their sexual activity over 2 years.
Present results showed diﬀerences comparing HPV dis-
tribution regarding education level and HPV vaccination.
Since the median age of ﬁrst sexual intercourse was of 16.0
years old, it is expected that university students have more
years of sexual life than nonuniversity students. Therefore,
they would be exposed more frequently to a HPV infection
than nonuniversity students. Regarding HPV vaccination,
sincetheNationalprogramofVaccinationinPortugalstarted
to include the HPV vaccine 2 years ago for girls between
13 and 18 years old, it is expected that these girls would be
protected from acquiring an HPV infection. Therefore our
data is correlated to these evidences and vaccination may
reduce eﬃciently the infection by HPV.
Despite these important epidemiological data, charac-
terization of HPV genotype frequencies among populations
is considered to be even more imperative. HPV diagnostic
assays such as hybrid capture second-generation (HC2) and
PCR-based methods employing the consensus primers,
MY09/11 and GP5+/6+, allow the detection of a large
number of HPV types, mainly high-risk types [28]. These
primersetshavebeenwidelyusedtostudythenaturalhistory
of HPVs and their role in the development of cervical cancer
[28, 41].
In our study, we have used the genotyping method
described by Nobre et al. in 2008, which allows a good dis-
crimination of mucosal HPV types, including several HPV
types that are underdiagnosed by current diagnostic meth-
ods. Our data showed that high-risk HPV types are the most
frequent, with HPV31 and HPV16 having higher frequency.
Surprisingly, HPV31 was found as the most frequent among
our study. A recent meta-analysis shows that HPV31 may be
the second or third most common type in European women
with normal cytology [40, 42]. Despite HPV18 is a prevalent
type worldwide and the second most common high-risk
type associated with cervical cancer development, it was not
among the more frequent in our study. However, HPV 18
infection leads to a rapid onset of cervical cancer [43], and it
isexpectedtobemorefrequentlyfoundinhigh-gradelesions
than in asymptomatic young women. Notably, 13 mucosal
HPV types that are not detected by the majority of current
commercial assays (HPV 34, 53, 61, 62, 66, 67, 70, 71, 73, 81,
83, 84, and 102) were detected in the present study.
Regarding our results, we must consider that after an
open invitation to participate in the study, all participants
were volunteers and informed of the study through work-
shops developed speciﬁcally to explain the study and self-
sampling procedure. We cannot rule out the inﬂuence of
two factors, that the attending students were more keen to
know more about HPV and that subjects at higher risk of
HPV infection are fear of being detected positive. However,
we do think that the inﬂuence of those factors was reduced
because knowing HPV results was optional, and only under
the supervision of the gynecologist. Furthermore, our rate
of participation was not conditioned by the cost of the test
(which was free to all participants).
Molecular pathology methodologies have been demon-
strated as important in the improvement of screening, diag-
nostic, or monitoring cancer,and genetic- or viral-associated
diseases. Furthermore, they provide valuable tools for the
new paradigm in Medicine known as personalized medicine
[44–46]. The new molecular biology procedures use tra-
ditionally diﬃcult material as in the case of formaldehyde
ﬁxation samples, and to analyse unstable molecules as in
the case of RNA, let us consider new possibilities in the
practical use of the new molecular pathology biomarkers.
Therefore,DNAandRNAvirusesareinthefrontlineofthese
possibilities due to their inﬂuencing of the development and
evolution of some diseases [47, 48]. In the case of HPV,
molecular epidemiology studies have been the key to the
opening of a window to vaccination against cervical cancer.
Several lines of evidence are demonstrating the putative role
of HPV molecular biology detection in the screening of
cervical cancer and its putative role in head and neck cancer
[49–52].
It is acceptable to consider that, to achieve the maximum
eﬃcacy in health prevention strategies, we must maximize
the knowledge of some populations about their epidemiol-
ogy, costumes, and concerns and that is particularly impor-
tant in those populations where no screening or vaccination
has already been developed [53–56]. This data reinforces the
urgency to perform genotyping studies to characterize the
HPV genotype distribution worldwide, so that preventive
and therapeutic strategies can be adapted to each population
according to the HPV genotypes distribution [1, 14].
In conclusion, we have to refer that self-sampling may
be a good alternative in substitution of the vaginal speculum
examination by a clinician as a tool for primary screening of
HPV infection in young asymptomatic women. This study
contributes to a better understanding of the epidemiology
of HPV infection among young Portuguese women. The
exact knowledge of HPV proﬁle in young women may be
important to appraise the vaccination strategies within the
diﬀerent population.
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